Track market-moving stories before they get noisy

Monday.com (MNDY - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this project management software developer have returned +16.2% over the past month versus the Zacks S&P 500 composite's +4.4% change. The Zacks Internet - Software industry, to which Monday.com belongs, has lost 2.2% over this period. Now the key question is: Where could the stock be headed in the near term?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Monday.com is expected to post earnings of $1.00 per share, indicating a change of -8.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $4.28 for the current fiscal year indicates a year-over-year change of -2.7%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $5.17 indicates a change of +20.8% from what Monday.com is expected to report a year ago. Over the past month, the estimate has changed +1.2%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Monday.com.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Monday.com, the consensus sales estimate for the current quarter of $354.95 million indicates a year-over-year change of +18.7%. For the current and next fiscal years, $1.47 billion and $1.7 billion estimates indicate +19.3% and +15.4% changes, respectively.

Last Reported Results and Surprise HistoryMonday.com reported revenues of $351.27 million in the last reported quarter, representing a year-over-year change of +24.5%. EPS of $1.15 for the same period compares with $1.1 a year ago.

Compared to the Zacks Consensus Estimate of $338.9 million, the reported revenues represent a surprise of +3.65%. The EPS surprise was +19.79%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Monday.com is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Monday.com. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

The U.S. IPO market maintained its strong momentum in May with 12 offerings raising $13.1 billion in total proceeds, which was well above April's $8.2 billion in total proceeds but one short on deal count. The largest deal of the month was technology firm Cerebras Systems' $6.4 billion raise, making it the largest IPO since Medline Inc.'s $7.2 billion raise in December 2025 and the biggest tech IPO since Uber Technologies' $8.1 billion in May 2019. The healthcare sector saw three new issuers, led by GMR Solutions' $478.7 million offering.

LONDON--(BUSINESS WIRE)--monday.com (Nasdaq: MNDY), the AI work platform that turns strategy into execution at scale, today announced Ben Barnett’s appointment to General Manager (GM) of Europe, the Middle East and Africa, marking a major milestone in the company’s global expansion.

The move comes as monday.com completes its biggest-ever transformation into an AI work platform.

Share Ben, who has been with monday.com for five years, brings a decade of experience in senior B2B sales roles at software companies and has overseen significant, sustained growth at monday.com in the UK and Ireland since joining in 2021.

In his new position, Ben’s priorities include delivering the monday.com’s EMEA go-to-market strategy, fostering key partnerships, and bolstering its newly announced AI work platform. He is based in London.

Ben’s promotion comes as monday.com builds on a period of rapid regional success, with EMEA revenue up 26% year-on-year in 2025. Last year, monday.com expanded its regional EMEA headquarters in Fitzrovia, London, now occupying 80,000 sq ft across three floors where more than 370 employees are based, as well as adding offices in Paris and Munich. There are more than 2,250 employees in monday.com’s EMEA region, encompassing London, Munich, Paris, Tel Aviv, and Warsaw.

monday.com has just completed the most significant change in its history, rebuilding its product from a work management solution to a single AI work platform, where people and agents execute, manage and operate as one team.

Ben Barnett, General Manager for EMEA at monday.com said: "EMEA has been one of monday.com's most exciting growth stories, and I've had the privilege of living it from the inside. It’s a unique privilege to be afforded the opportunity to lead a region with such a broad business and cultural history and nuance, bound together by a shared spirit of industry and enterprise. As we move now into an AI-powered age, I’m proud to step into this GM role and bring our customers the tools and advice they need to harness technology in a way, and at a speed, that works for them."

Casey George, Chief Revenue Officer at monday.com said: "Ben has been instrumental in shifting our EMEA business into a higher gear, consistently demonstrating the skill and precision required to scale in complex markets. He was there at the inception of our London office, and the breadth of knowledge, relationships and commercial instinct he has built across this region over five years is an extraordinary asset. He understands our customers, our partners and our people in a way that only comes from being in the room for every chapter of this growth story. With his leadership, we are strongly positioned to accelerate our annual plan and lead the next frontier of enterprise AI."

About monday.com

monday.com is the AI work platform that not only helps manage and orchestrate work, but also does the work for you. Over 250,000 customers worldwide use monday.com to bring people, workflows, and AI agents together on one flexible platform, where AI doesn't just assist, it executes. From work management and CRM to service and dev, every monday.com product runs on the same AI layer, automating tasks, running workflows, and helping teams deliver exponentially more with less effort.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Monday.com (MNDY - Free Report) .

Monday.com currently has an average brokerage recommendation (ABR) of 1.64, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 25 brokerage firms. An ABR of 1.64 approximates between Strong Buy and Buy.

Of the 25 recommendations that derive the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 64% and 8% of all recommendations.

Brokerage Recommendation Trends for MNDY

Check price target & stock forecast for Monday.com here>>>

The ABR suggests buying Monday.com, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1--5, they are different measures altogether.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.

There is also a key difference between the ABR and Zacks Rank when it comes to freshness. When you look at the ABR, it may not be up-to-date. Nonetheless, since brokerage analysts constantly revise their earnings estimates to reflect changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in predicting future stock prices.

Is MNDY Worth Investing In?Looking at the earnings estimate revisions for Monday.com, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $4.49.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Monday.com. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Mondaycom.

Item 1 of 2 A logo of Blackstone is pictured in Manhattan, New York City, U.S. July 29, 2025. REUTERS/Mike Segar/File Photo

[1/2]A logo of Blackstone is pictured in Manhattan, New York City, U.S. July 29, 2025. REUTERS/Mike Segar/File Photo Purchase Licensing Rights, opens new tab

CompaniesJune 3 (Reuters) - Canadian power producer TransAlta Corp (TA.TO), opens new tab said on Wednesday it ​will acquire two natural gas-fired peaking facilities near Denver, ‌Colorado, from Blackstone (BX.N), opens new tab for about $1 billion, strengthening its presence in the Western U.S. power market.

Power producers are adding flexible gas-fired capacity to support rising ​demand, as the industry prepares for a rapid growth ​in electricity consumption, partly driven by power-hungry data centers.

Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.

The ⁠assets, Mountain Peak Power and Canyon Peak Power, have ​a combined capacity of 318 megawatts and are fully contracted under ​long-term tolling agreements with investment-grade customers for more than 25 years.

The deal includes assuming $750 million of project-level debt and raising about $250 million in equity ​through a C$350 million bought deal share offering.

Under the ​offering, a syndicate of underwriters led by CIBC Capital Markets and RBC Capital ‌Markets ⁠will buy 18.2 million shares at C$19.20 each.

The facilities are expected to generate about $80 million in annual adjusted core profit and roughly $33 million in free cash flow, with additional upside ​from performance incentives.

"These ​assets will ⁠generate long-term contracted cash flows for redeployment into other growth prospects such as Centralia and Alberta ​data centres," CEO Joel Hunter said.

TransAlta said ​the deal ⁠will be immediately add to free cash flow per share in the low-to-mid single digits.

The transaction is expected to close in ⁠early ​fourth-quarter 2026, subject to the completion ​of the Canyon Peak facility, which is set to begin operations in the ​third quarter.

Reporting by Sumit Saha in Bengaluru; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles., opens new tab

IPO watch 2024: Which new stocks will hit the market?Apogee Therapeutics NASDAQ: APGE executives said the company is preparing to move its lead drug candidate, zumilokibart, into Phase 3 testing later this year after reporting Phase 2b data in atopic dermatitis and securing a major financing agreement with Blackstone.

Speaking at a Jefferies-hosted event, Michael Henderson, chief executive officer of Apogee Therapeutics, said zumilokibart, or Zumi, is being developed for Type 2 inflammatory diseases, with atopic dermatitis as the lead indication. Henderson said the company’s recently released Phase 2b data showed “very competitive efficacy” with four dosing days during induction. He also said data released earlier this year showed that dosing every three to six months after induction could maintain efficacy and lead to improved responses over time.

Get Apogee Therapeutics alerts:

Henderson said Apogee believes Zumi could become “the next exciting launch in frontline atopic dermatitis” and described the company’s broader plans as including asthma and eosinophilic esophagitis. He said Apogee sees “full pipeline and product potential” for Zumi later this decade.

Blackstone Financing Removes Near-Term Funding Overhang, Executives Say Apogee executives highlighted the company’s $1.3 billion financing collaboration with Blackstone as a key part of its strategy entering Phase 3. Henderson said the agreement, combined with the company’s existing balance sheet, gives Apogee cash “through launch and even commercialization and profitability.” He said the company now enters Phase 3 “without a financing overhang.”

Jane Pritchett Henderson, Apogee’s chief financial officer, said the Blackstone transaction was the “largest pre-Phase 3 deal” of its type and reflected Blackstone’s conviction in Zumi. She said Apogee focused on three priorities in negotiations: the amount of capital available, the cost of capital and strategic optionality.

Pritchett Henderson said the capital available under the deal means Apogee has “no need for equity.” She added that Apogee negotiated royalty rates that decline with sales, flexibility around how much capital to draw down and a potential future option to buy down the royalty to a “very low single-digit royalty rate,” if appropriate. She also said the agreement does not include “onerous governance features.”

Asked about whether the financing affects strategic optionality, Michael Henderson said companies want to be in “a position of strength, not weakness” in any strategic discussion. He said Apogee now has a clear independent path to launch Zumi if that is the best route, while also noting that another company with a lower cost of capital could potentially accelerate combination development or indication expansion.

Company Positions Zumi as a Frontline Atopic Dermatitis Therapy Jeff Hartness, Apogee’s chief commercial officer, said Zumi is being positioned as a first-line biologic option in atopic dermatitis after topical therapies. He compared the potential commercial setup to the launch of Skyrizi in plaque psoriasis, saying that product gained broad uptake despite launching into a competitive market because it offered an extended dosing option.

Hartness said dosing frequency and patient persistence are important for patients, physicians and payers. He said Dupixent has about a 73% persistence rate in the first year and that roughly half of patients discontinue by the end of the second year. By comparison, he said Skyrizi in plaque psoriasis has a first-year persistence rate of about 95%.

Hartness said higher persistence can reduce office visits, use of additional therapies and switching. He said switching matters to payers because patients often restart induction dosing on a new product, which is more costly. He argued that Zumi’s dosing profile — four dosing days during induction and two to four dosing days per year in maintenance — could make it appealing as an initial biologic choice in atopic dermatitis.

Development Strategy Includes Dose Finding in New Therapeutic Areas Carl Dambkowski, Apogee’s chief medical officer, said the company is taking a deliberate approach to dose optimization as it expands Zumi into additional indications. He said Apogee wants to balance speed with ensuring that it selects the right dose to maximize efficacy.

Dambkowski said Apogee’s atopic dermatitis work showed the value of dose optimization, saying the company could have either selected a less convenient dose with a higher injection burden or underdosed the drug and missed additional efficacy. He cited the company’s top-line atopic dermatitis data, including 65% EASI 75, more than 40% placebo-adjusted EASI 75, and mid-40% rates for both EASI 90 and IGA 0/1, with placebo-adjusted results in the mid-30% range.

For dermatology indications, Dambkowski said the company now believes it has an optimized dose that could support expansion into other dermatologic diseases without repeating dose-ranging studies. He listed prurigo nodularis, bullous pemphigoid and chronic spontaneous urticaria as examples of potential dermatology opportunities.

In respiratory disease, however, Dambkowski said Apogee plans to conduct dose-ranging work in asthma before moving into additional respiratory indications such as COPD, allergic rhinitis or chronic rhinosinusitis with nasal polyps. He said regulators historically want dose-ranging data within a therapeutic area because endpoints and disease trajectories vary.

Respiratory Combination Plans Expected Later This Year Dambkowski said Apogee expects to announce plans later this year for a combination involving Zumi and APG333, the company’s extended half-life TSLP program. He said timing for the start of that combination work could fall in 2027 or 2028, but more details are expected later.

For Zumi monotherapy in asthma and potentially COPD, Dambkowski said Apogee expects to focus on a Type 2-enriched population, using eosinophils above 150 as a marker. He said the potential Zumi-plus-APG333 combination could be aimed at a broader population, including patients with eosinophils below 150, where he said unmet need remains high.

Pritchett Henderson said a global Phase 2 trial could cost about $250,000 per patient. She said a combination trial could be larger than a monotherapy study, potentially up to 50% larger, with more details to come when the company discloses plans for the combination in the second half of the year.

APG279 Bar Depends on Zumi’s Atopic Dermatitis Performance Henderson also discussed APG279, Apogee’s IL-13 and OX40 ligand fixed-dose combination. He said the program is being tested head-to-head against Dupixent in an approximately 86-patient randomized trial.

Henderson said the better Zumi performs in atopic dermatitis, the higher the internal bar becomes for advancing APG279. He said physicians have indicated they would want to see about a 10-point delta, which he said implies a 15- to 20-point delta versus Dupixent in the current study for Apogee to justify allocating more capital.

If APG279 meets that bar, Henderson said it could show “profound efficacy” and potentially become a second-line option in atopic dermatitis, where he said JAK inhibitors are currently the main option. He said Apogee will know if the trial does not meet that threshold.

Henderson said Apogee’s top priorities remain Zumi approval in atopic dermatitis, followed by expansions into other indications. He said the company has invested in people, manufacturing and clinical research organization relationships ahead of key milestones, and that separate teams are focused on atopic dermatitis, asthma and eosinophilic esophagitis.

About Apogee Therapeutics NASDAQ: APGEApogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Apogee Therapeutics Right Now?Before you consider Apogee Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.

While Apogee Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

watch now

Blackstone is restricting withdrawals from its flagship Blackstone Private Credit, or BCRED, fund following a spike in investor redemption requests, as fears over liquidity pressures rattled private markets.

The asset management giant capped investor withdrawals from the $79 billion nontraded business development company at 5% of shares, after redemption requests hit 10% during the second quarter.

It comes after U.S. private markets giants sold off on Wednesday after Switzerland's Partners Group said it was curbing redemption requests in one of its European private equity vehicles.

Partners Group said on Thursday it was prepared to restrict withdrawals in more of its funds, warning that the spike in client withdrawals is now spreading from private credit into private equity.

Shares in Blackstone were up more than 5% in late-morning trading Thursday. They fell about 4% on Wednesday during the sell-off.

Blackstone.

BCRED is one of the first major semi-liquid private credit vehicles updating on investor redemption requests during the second quarter.

The cap comes after BCRED saw client redemption requests jump to a then-record of 7.9%, or about $3.8 billion, in the first quarter.

Blackstone fulfilled 100% of those requests by raising its quarterly cap and using employee capital to cover the remaining amount.

The fund drew inflows of about $1 billion during the first quarter, but ultimately recorded a net capital outflow after covering withdrawals.

"The idea that there are caps is really a feature, not a bug, of these products," Blackstone Chief Operating Officer and President Jon Gray told CNBC in March.

As Partners Group issued its update on Thursday, its CEO, David Layton, said, "Liquidity features are designed to protect long-term investors, and to ensure that returns continue to be driven by the quality of the underlying private assets rather than by short-term flow dynamics."

Last week, Daniel Ivascyn, Pimco's chief investment officer, warned that higher losses were coming for the credit industry.

"There's a lot going on beneath the surface," he said in a video shared by the company. "We are, we think, in the midst of the first sustained default or loss cycle in many, many years."

— CNBC's Leslie Picker contributed to this story.

Broadcom said it will partner with Apollo Global Management and Blackstone's credit and insurance business to launch a platform backed by an initial $35 billion to finance artificial-intelligence infrastructure.

Blackstone Inc. (BX) Presents at Morgan Stanley US Financials Conference 2026 Transcript

"The year of the IPO is definitely on," Martin Brand, head of Blackstone Capital Partners, says while speaking with Bloomberg's Dani Burger at the SuperReturn International Conference in Berlin. -------- More on Bloomberg Television and Markets Like this video?

IPO watch 2024: Which new stocks will hit the market?Apogee Therapeutics NASDAQ: APGE executives outlined plans to advance zumilokibart, the company’s IL-13-targeting antibody, into late-stage development for atopic dermatitis while expanding the program into asthma and eosinophilic esophagitis, during a Goldman Sachs discussion hosted by lead biotechnology equity research analyst Salveen Richter.

The company said its top priority remains moderate-to-severe atopic dermatitis, which Apogee described as the largest, fastest-growing and least-penetrated immunology and inflammation indication in its target markets. Executives said recent Phase 2 data support zumilokibart’s potential as a first-line product in atopic dermatitis, with a target launch by the end of the decade.

Get Apogee Therapeutics alerts:

Apogee said Phase 2 Part B induction data showed “robust efficacy” across lesion and itch endpoints with four dosing dates, compared with nine for the current standard of care. Earlier Phase 2 Part A maintenance data showed responses continued to improve through 52 weeks, including an EASI-100 rate of more than 40% among patients in the maintenance setting, according to the company.

Phase 3 Atopic Dermatitis Program Set to Begin Apogee said it plans to begin Phase 3 trials for zumilokibart in atopic dermatitis in the second half of the year. The program is expected to follow a standard design for the indication, including two replicate trials of about 400 patients each comparing zumilokibart with placebo, as well as a third trial in combination with topical corticosteroids to support labeling.

Executives said the Phase 2 Part B study was designed to replicate the strong results seen in Part A and to optimize dosing. The company said the mid-dose confirmed the product profile, while testing higher and lower doses helped determine whether additional efficacy could be achieved or whether lower dosing would be insufficient.

Jeff Hartness, Apogee’s chief commercial officer, said the company expects both every-three-month and every-six-month dosing to be included on the label. He said market research indicates physicians want dosing optionality and that some may initially use every-three-month dosing before transitioning patients to every-six-month dosing.

Hartness also emphasized the product’s itch profile, saying zumilokibart could allow physicians to manage both itch and lesions rather than choosing between the two. He compared the company’s itch data favorably with marketed therapies discussed during the session, including NEMLUVIO and JAK inhibitors.

Company Sees Large Market Opportunity Hartness said Apogee views zumilokibart as the “next first-line launch” in atopic dermatitis and described the market as one that could grow to $50 billion. He said biologic penetration is currently about 10%, leaving room for growth as additional therapies expand the market.

He said zumilokibart’s dosing schedule could be a key differentiator, with two to four dosing days per year versus 26 dosing days per year for DUPIXENT. Hartness also said recent product launches, including Ebglyss and NEMLUVIO, are expanding the market and that future oral agents could help move more patients from topical therapies to systemic treatment.

On market access, Hartness said Apogee’s strategy is to secure early frontline access and that the company has already begun discussions with payers. He said recent branded launches with limited differentiation from DUPIXENT have obtained frontline access, and he expects zumilokibart to do the same.

Hartness also said he does not expect potential DUPIXENT biosimilars, which could enter the market as early as 2031, to negatively affect access for zumilokibart. He said biosimilar competition typically affects the reference product directly rather than surrounding branded biologics.

Blackstone Financing Supports Commercial Plans Apogee executives also discussed the company’s recently announced collaboration with Blackstone Life Sciences, describing it as a non-dilutive financing designed to support development and commercialization. The company said the transaction includes access to up to $1.3 billion in capital, consisting of $800 million of royalty financing flexibility and up to $500 million of debt.

Executives said the financing, together with the company’s balance sheet, is expected to take Apogee through commercialization of zumilokibart in 2029 and potentially to profitability. The company said it focused on three priorities in the transaction: the amount of capital, cost of capital and strategic flexibility.

Apogee said the agreement does not include milestone payments back to Blackstone and includes royalty rates that scale down as sales grow. Executives also said a future strategic acquirer would have the option to buy down the royalty to a low-single-digit rate, which the company said was designed to preserve flexibility in a change-of-control scenario.

Pipeline Expansion in Asthma, EoE and Combination Programs Beyond atopic dermatitis, Apogee said it plans to start a Phase 2 trial in eosinophilic esophagitis in the second half of the year. The open-label study is expected to enroll 30 to 50 patients, with histology measured by eosinophil count as the primary endpoint. Executives said the study will also evaluate patient diaries and endoscopy.

The company also plans a Phase 2b study in moderate-to-severe asthma that it said could potentially be registrational. Apogee said the 500-patient trial will enrich for patients with eosinophils above 150 and a history of exacerbations, and will test three-month, six-month and 12-month dosing schedules. The company cited earlier data showing durable FeNO suppression out to eight months.

Apogee also highlighted two combination programs. Data for APG279, a coformulation targeting IL-13 and OX40 ligand, are expected in the second half of the year in a head-to-head study against DUPIXENT. The company said the bar for advancement is high and that it would not move the program forward unless it shows meaningful added efficacy over zumilokibart alone.

For APG273, which combines IL-13 and TSLP targeting, Apogee said it plans to disclose more details in the second half of the year. Executives said the combination could offer broader patient reach and potential efficacy advantages in respiratory indications, including asthma and COPD.

Apogee said its main objective is to bring zumilokibart to as many patients as possible as quickly as possible. Executives said the company now has the capital to advance the program independently, while noting that as a public company it would listen if a strategic party could demonstrate it could accelerate access to patients at a lower cost of capital.

About Apogee Therapeutics NASDAQ: APGEApogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Apogee Therapeutics Right Now?Before you consider Apogee Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.

While Apogee Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Chipotle Mexican Grill (CMG - Free Report) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.

Shares of this Mexican food chain have returned -9.4% over the past month versus the Zacks S&P 500 composite's +5.4% change. The Zacks Retail - Restaurants industry, to which Chipotle belongs, has lost 5.9% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Chipotle is expected to post earnings of $0.32 per share, indicating a change of -3% from the year-ago quarter. The Zacks Consensus Estimate has changed -0% over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $1.13 points to a change of -3.4% from the prior year. Over the last 30 days, this estimate has changed +0.1%.

For the next fiscal year, the consensus earnings estimate of $1.36 indicates a change of +19.8% from what Chipotle is expected to report a year ago. Over the past month, the estimate has changed +0.3%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Chipotle is rated Zacks Rank #3 (Hold).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Chipotle, the consensus sales estimate for the current quarter of $3.32 billion indicates a year-over-year change of +8.2%. For the current and next fiscal years, $12.93 billion and $14.34 billion estimates indicate +8.4% and +10.9% changes, respectively.

Last Reported Results and Surprise HistoryChipotle reported revenues of $3.09 billion in the last reported quarter, representing a year-over-year change of +7.4%. EPS of $0.24 for the same period compares with $0.29 a year ago.

Compared to the Zacks Consensus Estimate of $3.08 billion, the reported revenues represent a surprise of +0.41%. The EPS surprise was 0%.

Over the last four quarters, Chipotle surpassed consensus EPS estimates three times. The company topped consensus revenue estimates two times over this period.

ValuationWithout considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Chipotle is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Chipotle. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Chipotle Mexican Grill is rated Buy, with the market undervaluing its recovery potential at ~$28/share versus a DCF-derived intrinsic value of $40.48. I see current headwinds as cyclical, not structural, with operational catalysts—HEAP equipment rollout and loyalty program enhancements—already visible and measurable. CMG's unique company-owned, non-franchise model amplifies both downside volatility and upside leverage in recoveries, directly benefiting shareholders.

Chipotle Mexican Grill Inc (NYSE:CMG) stock is up 2.1% at $28.77 in premarket trading, after J.P. Morgan Securities upgraded the restaurant stock to "overweight" from "neutral," citing an attractive valuation opportunity. The firm also trimmed its price target to $35 from $38.

The bull note arrives after a brutal stretch on the charts for Chipotle stock. The shares plunged to a more than three-year low of $28.04 yesterday alongside a sixth-straight drop. CMG is down 46% over the last 12 months and roughly 13% in just the last week. Strengthening its case for a rebound, CMG sits in "oversold" territory, per its 14-day relative strength index (RSI) of 24.3.

The majority of analysts are already bullish on CMG. Heading into today, 25 of the 35 in coverage carry a "buy" or better rating, with 10 "holds" and no sells on the books. 

Options traders are pricing in relatively low volatility expectations, per Chipotle's Schaeffer's Volatility Index (SVI) of 38%, which sits in the 28th percentile of its annual range. Meanwhile, the stock's Schaeffer's Volatility Scorecard (SVS) of 93 out of 100 indicates it has consistently exceeded those expectations during the past year.

Key Takeaways CMG relaunched Rewards to widen enrollment and make ordering easier across digital and in-restaurant channels.CMG says 90% of app transactions link to Rewards vs. ~20% in-restaurant, creating a major attachment gap.CMG added gamification, monthly drops, Freepotle expansion and a planned single-scan feature to build habit. Chipotle Mexican Grill, Inc. (CMG - Free Report) is sharpening its loyalty strategy as it looks to convert stronger guest engagement into repeat traffic. The company’s refreshed Rewards program is designed to widen the funnel, deepen engagement with existing members and reduce friction across digital and in-restaurant ordering. The initiative comes as CMG works to sustain transaction momentum in a more cautious consumer environment.

The opportunity is meaningful because loyalty penetration remains uneven across channels. CMG stated that nearly 90% of app transactions are currently linked to Rewards, compared with only about 20% of in-restaurant transactions. That gap gives the company a meaningful opportunity to expand loyalty attachment beyond its digital-heavy customer base and into a major everyday ordering channel. To support that effort, CMG launched an in-restaurant campaign with menu panels and QR code signage while also incentivizing restaurant teams to promote the enhanced program. Early results have been positive, with daily enrollees rising nearly 25% following the relaunch.

The relaunch also builds on improving loyalty-driven sales trends. CMG stated that loyalty-driven comps have outpaced non-loyalty comps for several consecutive quarters, with the gap widening. In the first quarter of 2026, loyalty represented 32% of sales, up 300 basis points year over year, reflecting growth in active members and higher frequency among existing members. Also, emphasis on new features such as expanded reward choice, gamification, monthly Chipotle drops, Freepotle expansion and a planned single-scan feature bode well.

As consumer spending remains uneven across the restaurant industry, CMG’s Rewards relaunch gives the company a more targeted mechanism to influence customer behavior. Supported by a higher loyalty sales mix, stronger enrollment trends and a meaningful in-restaurant conversion opportunity, the program could become a more visible contributor to CMG’s transaction momentum if execution continues to improve.

Chipotle’s Competitive LandscapeChipotle shares competitive space with Starbucks Corporation (SBUX - Free Report) and McDonald’s Corporation (MCD - Free Report) in the restaurant industry’s push to drive traffic through loyalty, digital engagement and targeted customer activation.

Starbucks is benefiting from a more mature loyalty ecosystem that supports customer frequency and repeat routines. In the second quarter of fiscal 2026, Starbucks reported a record U.S. 90-day active Starbucks Rewards membership of 35.6 million, up 4% year over year. The company also noted that its new 60-star redemption option became its most-used reward, accounting for roughly one-third of all redemptions, while a growing number of customers visited four or more times per week after the program changes. Starbucks’ rewards platform is closely tied to habitual beverage occasions, giving it a strong base for recurring customer engagement.

Meanwhile, McDonald’s is using a broader traffic-generation framework built around value, marketing, menu innovation and digital activation. In the first quarter of 2026, the company reported global comparable sales growth of 3.8%, including 3.9% growth in the United States. McDonald’s also highlighted campaigns such as KPop Demon Hunters, which combined dual-daypart offers with digital activation in the McDonald’s app. This shows how the company is using digital channels to amplify value and marketing campaigns while staying relevant with digitally native consumers.

CMG operates differently within the loyalty landscape, with its opportunity tied to converting more restaurant guests into active Rewards users. While Starbucks has already built a high-frequency rewards model and McDonald’s is using digital activation within a broader value-led playbook, CMG is focused on narrowing the gap between app-linked and in-restaurant-linked Rewards transactions.

Overall, Starbucks benefits from a loyalty-driven frequency model, McDonald’s gains from value-led traffic initiatives supported by digital activation, while CMG’s opportunity rests on expanding Rewards adoption across its restaurant base. For CMG, stronger in-restaurant adoption and sustained member frequency will be central to determining whether the Rewards relaunch can become a more durable contributor to traffic growth.

CMG’s Price Performance, Valuation & EstimatesShares of Chipotle have declined 46.4% in the past year compared with the industry’s fall of 12.3%.

CMG One-Year Price Performance
Image Source: Zacks Investment Research

From a valuation standpoint, Chipotle trades at a forward price-to-sales ratio of 2.67, below the industry’s average of 3.15.

CMG’s P/S Ratio (Forward 12-Month) vs. Industry
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for CMG’s 2026 earnings per share (EPS) implies a year-over-year decline of 3.4%. The EPS estimates for 2026 have declined in the past 60 days.

EPS Trend of CMG Stock
Image Source: Zacks Investment Research

CMG’s Zacks RankChipotle stock currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

All fans who wear a soccer jersey to Chipotle restaurants in the U.S., Canada and U.K. on June 11, after 3 p.m. local time, can receive a buy-one-get-one free entrée1 Chipotle is releasing its first-ever limited-edition soccer jersey, with 53 jerseys available exclusively through the Chipotle Rewards Exchange2 Chipotle Rewards members who participate in the Matchday BOGO will unlock an exclusive digital badge through the brand's revamped "Rewards on Repeat" program , /PRNewswire/ -- Chipotle Mexican Grill (NYSE: CMG) is bringing soccer fandom to its restaurants across the U.S., Canada and U.K. this summer with its first-ever Matchday BOGO. On June 11, after 3 p.m. local time, fans wearing a soccer jersey to Chipotle restaurants can score a buy-one-get-one (BOGO) free entrée,1 while celebrating this summer's premier international soccer tournament.

Photo assets are available here: https://www.dropbox.com/scl/fo/c2i73p0dqkhx5ufqdfm41/AAmyBU2kr28OsfCR5vcGIgg?rlkey=1pih1pvd8q414oidsg8a79j5t&st=kqx1xgcd&dl=0

On June 11, after 3 p.m. local time, soccer fans who wear a jersey to participating Chipotle restaurants in the U.S., Canada and the U.K. can get a buy-one-get-one free entrée.

Chipotle's first-ever limited-edition soccer jersey features “Real Chipotle” on the front and the number 53 on the back, representing the brand’s 53 real ingredients. Only 53 jerseys will be available exclusively through the Chipotle Rewards Exchange for loyalty members in the U.S. as part of the brand's summer soccer celebration. Inspired by the Global Game: Chipotle's First-Ever Soccer Jersey
Chipotle is also unveiling a limited-edition soccer jersey inspired by global soccer culture and modern streetwear. The front of the jersey features "Real Chipotle," inspired by the use of the word "Real" in some of the sport's most iconic club names, a term that conveys legacy and prestige. At Chipotle, "Real" reflects the brand's purpose and commitment to Food with Integrity. The back of the jersey features the number 53, representing the number of Chipotle's ingredients, blending performance-inspired style with details rooted in the brand's real food values.

Only 53 jerseys will be made available exclusively through the Chipotle Rewards Exchange for loyalty members in the U.S., with winners receiving their jerseys ahead of the tournament final. Chipotle Rewards members can exchange 10 points for a chance to win a jersey from June 10 through June 24. Fans can sign up for Chipotle Rewards at www.chipotle.com/rewards and earn free Chips and Guac with a qualifying purchase after joining.

"Every four years, this tournament creates an unmatched sense of excitement, pride and community among fans around the world," said Stephanie Perdue, Senior Vice President of Brand Marketing at Chipotle. "We wanted to celebrate the rituals that make the experience so memorable, from wearing lucky jerseys to gathering for matchday meals with Chipotle."

The Matchday BOGO builds on Chipotle's fan-favorite jersey promotions, including this year's Hockey Jersey BOGO, which became the most successful jersey-themed offer in the company's history.

Rewards Members Score More
Chipotle Rewards members who participate in the Matchday BOGO will unlock an exclusive digital badge through Chipotle's newly reimagined "Rewards on Repeat" program, which offers members more frequent rewards and greater flexibility. Guests must scan for Chipotle Rewards at the register to score the limited-edition badge.

Supporting Soccer Beyond Matchday
Chipotle continues to invest in soccer communities through grassroots fundraising initiatives across North America. In 2025 alone, the brand supported nearly 1,500 local soccer fundraisers, donating more than $225,000. Since launching its fundraiser program in 2015, Chipotle has supported more than 14,000 soccer fundraisers and contributed over $3.5 million to local soccer organizations.

1 — The Matchday BUY-ONE-GET-ONE (BOGO) promotion is limited to five free entrée items per check and is subject to availability. Each free item requires purchase of an entrée item of equal or greater value and may be collected only by the jersey-wearing guest. Valid only on June 11, 2026, after 3 p.m. local time. Redeemable in-restaurant only, at participating locations in the U.S., Canada and U.K.; not valid for catering, mobile, online or delivery orders. Kids' Meals do not count as an entrée purchase. Purchased entrées are eligible for Chipotle Rewards points in the U.S. and Canada; the promotion may not otherwise be combined with other coupons, promotions or special offers. Additional restrictions may apply; void where prohibited.

2 — NO PURCHASE NECESSARY. Open to legal residents of the 50 U.S. & D.C., 13+ who are Chipotle Rewards members. Promotion Period: 6/10/26 at 12:01 a.m. PT – 6/24/26 at 11:59 p.m. PT. Mail-in entries must be postmarked by 6/24/26 and received by 7/1/26. For Official Rules including how to enter, free entry method, entry limitations, odds, prize descriptions and complete details visit chipotle.com/soccer-jersey-sweeps. Sponsor: CMG Strategy Co., LLC.

ABOUT CHIPOTLE
Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. There are over 4,100 restaurants as of March 31, 2026, in the United States, Canada, the United Kingdom, France, Germany, and the Middle East and it is the only restaurant company of its size that owns and operates all its restaurants in North America and Europe. With over 135,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. For more information or to place an order online, visit www.chipotle.com.

SOURCE Chipotle Mexican Grill

It's tough being in the dining-out business right now. Soaring food costs are keeping families at home.

In the latest close session, Chipotle Mexican Grill (CMG - Free Report) was up +1.81% at $30.42. The stock's change was more than the S&P 500's daily loss of 1.62%. Meanwhile, the Dow lost 1.87%, and the Nasdaq, a tech-heavy index, lost 1.98%.

The stock of Mexican food chain has fallen by 8.54% in the past month, lagging the Retail-Wholesale sector's loss of 6.71% and the S&P 500's loss of 0.03%.

Investors will be eagerly watching for the performance of Chipotle Mexican Grill in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on July 29, 2026. On that day, Chipotle Mexican Grill is projected to report earnings of $0.32 per share, which would represent a year-over-year decline of 3.03%. Meanwhile, our latest consensus estimate is calling for revenue of $3.32 billion, up 8.25% from the prior-year quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.13 per share and a revenue of $12.93 billion, representing changes of -3.42% and +8.4%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Chipotle Mexican Grill. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.01% rise in the Zacks Consensus EPS estimate. Chipotle Mexican Grill currently has a Zacks Rank of #3 (Hold).

Looking at valuation, Chipotle Mexican Grill is presently trading at a Forward P/E ratio of 26.41. This valuation marks a premium compared to its industry average Forward P/E of 20.26.

One should further note that CMG currently holds a PEG ratio of 1.92. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Retail - Restaurants industry had an average PEG ratio of 1.79.

The Retail - Restaurants industry is part of the Retail-Wholesale sector. At present, this industry carries a Zacks Industry Rank of 208, placing it within the bottom 15% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CMG in the coming trading sessions, be sure to utilize Zacks.com.

CMG stock slumps 38% in a year as softer demand and margin pressure weigh on sentiment, raising questions about whether patience is the better play.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zynex (ZYXIQ) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Zynex securities between February 25, 2021 to December 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) --

What’s Happening?

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (OTCPK: ZYXIQ) in the The United States District Court District of Colorado on behalf of all persons and entities who purchased or otherwise acquired Zynex securities between February 25, 2021 to December 15, 2025, both dates inclusive (the “Class Period”).Investors have until April 21, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?

The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) Zynex shipped products, including electrodes, in excess of need; (b) as a result of this practice, the Company inflated its revenue; (c) the Company’s practice of filing false claims drew scrutiny from insurers, including Tricare; (d) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and sought more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023; (e) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations; (f) the Company was not committed to maintaining a strong internal control environment; (g) the Company’s order growth was a result of illegal overbilling; (h) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (i) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. What are the Next Steps?

If you purchased or otherwise acquired Zynex shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zynex, Inc. (OTC PINK: ZYXIQ).

Shareholders who purchased shares of ZYXIQ during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form-2/?id=185410&from=4

CLASS PERIOD: February 25, 2021 to December 15, 2025

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Zynex shipped products, including electrodes, in excess of need; (b) as a result of this practice, the Company inflated its revenue; (c) the Company's practice of filing false claims drew scrutiny from insurers, including the health insurance program, Tricare; (d) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and seeking more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023; (e) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations; (f) the Company was not committed to maintaining a strong internal control environment; (g) the Company's order growth was a result of illegal overbilling; (h) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (i) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The audit committee defendants, acting knowingly or with reckless disregard of the underlying fraud, helped the insiders bolster the Company's stock price through stock repurchase plans, and even by buying back millions of dollars worth of stock directly from Sandgaard, indicating their supposed belief that the stock was undervalued.

DEADLINE: April 21, 2026 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/zynex-inc-loss-submission-form-2/?id=185410&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ZYXIQ during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 21, 2026. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm

New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zynex, Inc. (OTC Pink: ZYXIQ) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zynex securities between February 25, 2021 and December 15, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/ZYXIQ.

Zynex Case Details

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors that:

(1) Zynex shipped products, including electrodes, in excess of need;

(2) as a result of this practice, the Company inflated its revenue;

(3) the Company's practice of filing false claims drew scrutiny from insurers, including Tricare;

(4) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and sought more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023;

(5) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations;

(6) the Company was not committed to maintaining a strong internal control environment;

(7) the Company's order growth was a result of illegal overbilling;

(8) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and

(9) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What's Next for Zynex Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/ZYXIQ, or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Zynex you have until April 21, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Zynex Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Zynex Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising.
Prior results do not guarantee similar outcomes.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292485

Source: Bronstein, Gewirtz & Grossman, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - April 15, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTC Pink: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) Zynex shipped products, including electrodes, in excess of need; (b) as a result of this practice, the Company inflated its revenue; (c) the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (d) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and sought more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023; (e) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations; (f) the Company was not committed to maintaining a strong internal control environment; (g) the Company's order growth was a result of illegal overbilling; (h) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (i) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On March 11, 2025, after the market closed, Zynex reported its fourth quarter and full year 2024 financial results, revealing a significant revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." Zynex further revealed "Tricare has temporarily suspended payments as they review prior claims." Tricare is the health insurance program for the U.S. military, and Zynex's largest customer, accounting for 20-25% of revenue.

On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025, on unusually heavy trading volume.

Then, on July 31, 2025, the full extent of Defendants' misdeeds were revealed when the Company acknowledged that it had not been in compliance with industry regulations. Also that day, the Company remarked on the "transformational" leadership change during the quarter with the appointment of new Chief Executive Officer ("CEO") Steven Dyson ("Dyson") to replace Sandgaard, and the announced departure of the Company's Chief Financial Officer ("CFO") Daniel Moorhead ("Moorhead"). The Company also temporarily suspended revenue and profitability guidance.

On August 1, 2025, the stock fell from the previous day's $2.23 per share to $1.26 per share, a 45% decline in heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Zynex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Zynex class action, go to www.faruqilaw.com/ZYXIQ or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292511

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Zynex, Inc. (“Zynex” or the “Company”) (OTC: ZYXIQ) between February 25, 2021 and December 15, 2025, inclusive.

Should You Join The Zynex Class Action Litigation?

Do you, or did you, own shares of Zynex, Inc. (OTC: ZYXIQ)?
Did you purchase your shares between February 25, 2021 and December 15, 2025, inclusive?
Did you lose money in your investment in Zynex, Inc.?
What To Do Next:

If you purchased or acquired Zynex securities, and/or would like to discuss your legal rights and options please visit Zynex, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].

If you wish to serve as lead plaintiff for the Class, you must file papers by April 21, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About The Lawsuit:

According to the lawsuit, Defendants made misrepresentations concerning the Company’s reported revenue stemming from its participation in a fraudulent overbilling scheme between 2018 and 2023.

About Bernstein Liebhard:

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.

ATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
[email protected]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zynex To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Zynex between February 25, 2021 and December 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

, /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (OTCPK: ZYXIQ) and reminds investors of the April 21, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

James (Josh) Wilson, Faruqi & Faruqi Senior Partner (PRNewsfoto/Faruqi & Faruqi, LLP) Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) Zynex shipped products, including electrodes, in excess of need; (b) as a result of this practice, the Company inflated its revenue; (c) the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (d) on August 21, 2023, Travelers commenced an action against Zynex, Sandgaard, Lucsok and Fox in the Superior Court of California alleging that Zynex and the defendants had embarked on a fraudulent overbilling scheme and sought more than $23 million in damages and civil penalties relating to hundreds of fraudulent claims between 2018 and 2023; (e) management had prioritized aggressive sales strategies to drive orders over compliance with industry laws, rules and regulations; (f) the Company was not committed to maintaining a strong internal control environment; (g) the Company's order growth was a result of illegal overbilling; (h) as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (i) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On March 11, 2025, after the market closed, Zynex reported its fourth quarter and full year 2024 financial results, revealing a significant revenue "shortfall" in the quarter "due to slower than normal payments from certain payers." Zynex further revealed "Tricare has temporarily suspended payments as they review prior claims." Tricare is the health insurance program for the U.S. military, and Zynex's largest customer, accounting for 20-25% of revenue.

On this news, Zynex's stock price fell $3.59 per share, or 51.3%, to close at $3.41 per share on March 12, 2025, on unusually heavy trading volume.

Then, on July 31, 2025, the full extent of Defendants' misdeeds were revealed when the Company acknowledged that it had not been in compliance with industry regulations. Also that day, the Company remarked on the "transformational" leadership change during the quarter with the appointment of new Chief Executive Officer ("CEO") Steven Dyson ("Dyson") to replace Sandgaard, and the announced departure of the Company's Chief Financial Officer ("CFO") Daniel Moorhead ("Moorhead"). The Company also temporarily suspended revenue and profitability guidance.

On August 1, 2025, the stock fell from the previous day's $2.23 per share to $1.26 per share, a 45% decline in heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. 

Faruqi & Faruqi, LLP also encourages anyone with information regarding Zynex's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Zynex class action, go to www.faruqilaw.com/ZYXIQ or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

SOURCE Faruqi & Faruqi, LLP